April 24 (Reuters) - Zyversa Therapeutics Inc ZVSA.O:
ZYVERSA THERAPEUTICS CEO ISSUES SHAREHOLDER LETTER ANNOUNCING TRANSFORMATIVE RESEARCH AND DEVELOPMENT TRENDS FOR INFLAMMASOME INHIBITORS, AND PROVIDES UPDATE ON INFLAMMASOME ASC INHIBITOR IC 100’S DEVELOPMENT STATUS
Source text: ID:nGNX163Pxd
Further company coverage: ZVSA.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.